Esperion Therapeutics Inc  

(Public, NASDAQ:ESPR)   Watch this stock  
Find more results for ESPR
44.34
+2.03 (4.80%)
Jun 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 41.42 - 44.54
52 week 9.40 - 48.21
Open 43.17
Vol / Avg. 1.17M/639,227.00
Mkt cap 1.05B
P/E     -
Div/yield     -
EPS -4.47
Shares 22.59M
Beta 2.77
Inst. own 98%
Aug 2, 2017
Q2 2017 Esperion Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 21, 2017
Esperion Therapeutics Inc at JMP Securities Life Science Conference
Jun 7, 2017
Esperion Therapeutics Inc at Jefferies Healthcare Conference
May 23, 2017
Esperion Therapeutics Inc at UBS Global Healthcare Conference - Webcast
May 17, 2017
Esperion Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference
May 4, 2017
Q1 2017 Esperion Therapeutics Inc Earnings Release
Apr 17, 2017
Esperion Therapeutics Inc Annual Shareholders Meeting - Webcast
Apr 4, 2017
Esperion Therapeutics Inc at Needham Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -70.73% -27.73%
Return on average equity -77.24% -29.07%
Employees 44 -
CDP Score - -

Address

3891 Ranchero Dr Ste 150
ANN ARBOR, MI 48108-2837
United States - Map
+1-734-8873903 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Officers and directors

Timothy M. Mayleben President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Narendra D. Lalwani Ph.D., FAHA, DABT Chief Operating Officer, Executive Vice President - Research & Development
Age: 64
Bio & Compensation  - Reuters
Mary P. McGowan M.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Nicole Vitullo MBA Independent Lead Director
Age: 59
Bio & Compensation  - Reuters
Roger S. Newton Ph.D., FAHA, FACN Director
Age: 66
Bio & Compensation  - Reuters
Scott N. Braunstein M.D. Independent Director
Age: 53
Bio & Compensation  - Reuters
Dov A. Goldstein M.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Antonio M. Gotto Jr., M.D., Ph.D. Independent Director
Age: 82
Bio & Compensation  - Reuters